Innovative Research Award
Xiao Dong is a researcher associated with Shanghai University whose academic work includes cancer-related biomaterials, nanomedicine, tumor-responsive therapeutic systems, and cancer immunotherapy. His scholarly profile identifies research activity at the interface of biomedical materials, drug-delivery technology, tumor biology, and therapeutic innovation.[1]
Abstract
This academic recognition profile summarizes the research record of Xiao Dong in the broad subject area of cancer, with particular emphasis on biomedical materials, nanomedicine, tumor-responsive therapeutic platforms, and cancer immunotherapy. Recent published research associated with Dong includes the development of a hypochlorous acid-responsive prodrug nanoplatform designed to integrate tumor-responsive drug activation with immunotherapeutic mechanisms[1]
Keywords
Cancer, cancer immunotherapy, nanomedicine, biomaterials, tumor microenvironment, drug delivery, prodrug nanoplatform, tumor-responsive therapy, STING agonist, biomedical engineering, anticancer therapeutics, immune response, translational research, Shanghai University, medical research, therapeutic innovation.[2]
Introduction
Cancer research increasingly integrates molecular biology, immunology, materials science, pharmacology, and bioengineering to address challenges associated with treatment resistance, tumor heterogeneity, systemic toxicity, and the immunosuppressive tumor microenvironment. Nanomedicine represents one interdisciplinary approach in which engineered materials are investigated as carriers or responsive platforms for delivering therapeutic agents to tumors.[2]
Research Profile
Xiao Dong is associated with Shanghai University in China. Published work identifies affiliations that include Shanghai 411 Hospital/Shanghai University and the Institute of Artificial Intelligence and Biomanufacturing within the School of Medicine at Shanghai University. His ORCID identifier is 0000-0001-6897-6999, providing a persistent identifier for attribution and discovery of scholarly activity. [3]
Research Contributions
A notable component of Xiao Dong’s research concerns the application of engineered nanomedicine systems to cancer therapy. In a 2026 study published in Biomaterials Research, Dong and collaborators reported a hypochlorous acid-responsive prodrug nanoplatform for synergistic cancer immunotherapy. The experimental system combined a stimulus-responsive methylene blue–doxorubicin dimer prodrug with a stimulator of interferon genes agonist, with the objective of coordinating tumor-responsive therapeutic activity and antitumor immune stimulation. [3]
Publications
Hypochlorous Acid-Responsive Prodrug Nanoplatform for Synergistic Cancer Immunotherapy. Published in Biomaterials Research in 2026, this investigated a responsive prodrug nanoplatform combining chemotherapy-related mechanisms with immune activation for experimental cancer treatment.Tumor Metabolism-Rewriting Nanomedicines for Cancer Immunotherapy. [4]
Research Impact
The supplied Scopus indicators report 30 indexed documents, 1,898 citations, and an h-index of 17 for Xiao Dong. These figures indicate that a portion of the researcher’s indexed scholarly output has received citation attention from subsequent academic literature. The h-index represents a combined measure of publication productivity and citation distribution, while the total citation count describes citation reception across indexed documents. [4]
Award Suitability
For consideration under an Innovative Research Award in the subject area of cancer, Xiao Dong’s documented research record presents several academically relevant characteristics. These include participation in multidisciplinary cancer research, development and evaluation of tumor-responsive therapeutic platforms, integration of nanomedicine with immunotherapeutic mechanisms, and contribution to research examining biological barriers within the tumor microenvironment. [5]
Conclusion
Xiao Dong’s research profile reflects interdisciplinary work in cancer-related biomaterials, nanomedicine, tumor-responsive therapeutic systems, and cancer immunotherapy. Published research demonstrates engagement with strategies designed to combine targeted or stimulus-responsive drug activity with modulation of antitumor immunity.[5]
External Links
References
- Elsevier. (n.d.). Scopus author details: Xiao Dong, Author ID 56457039700. Scopus.
https://www.scopus.com/authid/detail.uri?authorId=56457039700
- ORCID. (n.d.). ORCID record: Xiao Dong, 0000-0001-6897-6999. ORCID.
https://orcid.org/0000-0001-6897-6999
- Medical Lab Scientist Awards. (n.d.). Medical Lab Scientist Awards academic and scientific recognition platform.
https://medicallabscientist.com/
- Xia, S., Wang, X., Liu, C., Ji, R., Wang, M., Zhang, C., Chen, L., Chen, W., Yao, S. Q., Fang, C., & Dong, X. (2026). Hypochlorous Acid-Responsive Prodrug Nanoplatform for Synergistic Cancer Immunotherapy. Biomaterials Research, 30, Article 0300.
https://doi.org/10.34133/bmr.0300
- Wang, X., Liu, C., Ji, R., Liu, J., Shao, Y., Xia, S., Li, J., Zhang, X., Luo, L., Wu, Y., Yao, S. Q., Fang, C., Chen, L., & Dong, X. (2026). Lipid droplet-targeted biomimetic liposomes potentiate chemo-ferroptosis therapy in leukemia. Advanced Materials.
https://doi.org/10.1002/adma.202515716